



Please Direct All Correspondence to Customer Number **20995**

**TRANSMITTAL LETTER  
INFORMATION DISCLOSURE STATEMENT**


Applicant : Weber, et al.  
App. No : 10/828,795  
Filed : April 21, 2004  
For : COMPOSITIONS FOR AFFECTING  
WEIGHT LOSS  
Examiner : Sharon Brooks  
Art Unit : 1614

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

August 31, 2005

(Date)


  
Sam K. Tahmassebi, Reg. No. 45,151


**Mail Stop Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement and PTO/SB/08 equivalent listing references for consideration:
  - (X) Listing 7 references.
  - (X) Enclosing 7 references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

  
Sam K. Tahmassebi  
Registration No. 45,151  
Attorney of Record  
Customer No. 20,995  
(619) 235-8550



## INFORMATION DISCLOSURE STATEMENT


Applicant : Weber, et al.  
App. No : 10/828,795  
Filed : April 21, 2004  
For : COMPOSITIONS FOR AFFECTING  
WEIGHT LOSS  
Examiner : Sharon Brooks  
Art Unit : 1614

## CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

August 31, 2005

(Date)

  
Sam K. Tahmassebi, Reg. No. 45,151

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 7 references to be considered by the Examiner. Also enclosed are 7 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the mailing date of a final action and before the mailing date of a Notice of Allowance.

CERTIFICATION UNDER 37 C.F.R. § 1.97(e)(1)

I hereby certify that each item of information contained in this Statement was first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than Three months prior to the filing of this Information Disclosure Statement.

Thus, no fee is required as set forth in 37 C.F.R. § 1.97(c).

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: Aug. 31, 2005

By: 


Sam K. Tahmassebi  
Registration No. 45,151  
Attorney of Record  
Customer No. 20,995  
(619) 235-8550

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application No.	10/828,795
Filing Date	April 21, 2004
First Named Inventor	Eckard Weber
Art Unit	1614
Examiner	Sharon Brooks
Attorney Docket No.	OREX.001A

(Multiple sheets used when necessary)

SHEET 1 OF 1



## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	1	Spigset, et al. <i>Therapeutic Approaches to Bulimia Nervosa, Expert Opinion on Therapeutic Patents</i> , Vol. 11, No. 3, 2001, Pages 463-477; XP002292382	
	2	Islam, et al. <i>Naltrexone, Serotonin Receptor Subtype Antagonists, and Carbohydrate Intake in Rats, Pharmacology Biochemistry and Behavior</i> , Vol. 48, No. 1, 1994, pages 193-201; XP002292383	
	3	Olszewski, et al. <i>Evidence of Interactions Between Melanocortin and Opioid Systems in Regulation of Feeding, Neuroreport</i> , Vol 12, No. 8, June 13, 2001, pages 1727-1730; XP009035026.	
	4	Zhu, et al. <i>Pharmacologic Treatment of Eating Disorders, Canadian Journal of Psychiatry</i> , Vol 47 No. 3, April 3, 2002 pages 227-234; XP009035028	
	5	Werneke, et al. <i>Options for Pharmacological Management of Obesity in patients Treated with Atypical Antipsychotics, International Clinical Psychopharmacology</i> , Vol 17 No. 4, 2002, pages 145-160; XP009035036	
	6	Fuller et al., <i>Fluoxetine: A Serotonergic Appetite Suppressant Drug, Drug Development Research</i> , Vol. 17, No. 1, 1989, pages 1-15; XP009035038.	
	7	International Preliminary Examination Report PCT Application PCT/US2004/012393, mailed on June 29, 2005.	

1906871  
083105

Examiner Signature

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.